请输入您要查询的百科知识：

　

词条 List of patient-reported quality of life surveys
释义

  1. List

  2. References

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List

  • Alzheimer's disease. The Quality of Life of Carers of Alzheimer’s Disease Patients (ACQLI) is a measure which assesses the quality of life of people who care for Alzheimer's disease patients. It was developed in 1997 by Galen Research[1] and has been used in studies investigating rosiglitazone[2][3][4] and the effects of pharmacological treatment.[5]
  • Angina. The Seattle Angina Questionnaire (SAQ) measures five dimensions of coronary disease and consists of 19 items.[6] The SAQ has been utilized in studies investigating spinal cord stimulation,[7] ivabradine and ranolazine[8] and refractory angina pectoris.[9]
  • Ankylosing spondylitis. The Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) was developed Galen Research and published in 2003.[10] It has been used in the evaluation of adalimumab[11][12] and etanercept.[13][14]
  • Asthma.
    1. The Adult Asthma Quality of Life Questionnaire (AQLQ) was developed at McMaster University in Ontario, Canada and was published in 1992.&91;15&93; It has since been used as a comparison tool&91;16&93; as well as a tool in clinical trials.&91;17&93;&91;18&93;
    2. The Asthma Life Impact Scale (ALIS) measure was developed in 2010 by Galen Research.&91;19&93; It has been translated into 16 languages.&91;20&93;
    3. Atopic dermatitis.
    4. The Parents’ Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis has on quality of life, from the parents’ perspective.&91;21&93; It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.&91;22&93; It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.&91;23&93;&91;24&93;&91;25&93; and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.&91;26&93;
    5. The Quality of Life Index for Atopic Dermatitis (QoLIAD) measures the impact that atopic dermatitis has on a given patient’s quality of life.&91;27&93; It is a 25 item questionnaire for patients over the age of 16.&91;28&93; The QoLIAD has also been utilized in studies looking into educational intervention,&91;29&93;&91;30&93; topical corticosteroids&91;31&93; and pimecrolimus.&91;32&93;
    6. Arthroplasty (Knee replacement).The Oxford knee score (OKS) is owned by Isis Outcomes and was developed at Oxford University. It was published in 1998.[33] It has been validated for use in assessing other non-surgical treatments for issues of the knee.[34]
    7. Chickenpox. The Family Disruption Measure for Chickenpox was developed in 1994 by Galen Research.[35] It has been used in a study investigating rotavirus gastroenteritis.[36]
    8. Chronic obstructive pulmonary disease. The Living with Chronic Obstructive Pulmonary Disease questionnaire (LCOPD) has 22 yes or no questions and measures a patient's quality of life.[37] It has been translated into 14 languages[38] and also been used in an investigation of fatigue, sleep loss and mood for patients with COPD.[39]
    9. Depression. The Quality of Life in Depression Scale (QLDS) assesses the impact that depression has on a patient’s quality of life.[40] It was developed by Galen Research in 1992 and was funded by Lilly Industries.[41] Studies utilizing the QLDS include investigations into venlafaxine,[42] duloxetine[43][44][45] and bupropion.[46]
    10. Diabetes. The Diabetes Health Profile (DHP) was developed in 1996 by Isis Outcomes. It has been officially adapted into 29 languages and was selected by the United Kingdom Department of Health for their Long Term Conditions PROM Pilot Study.
    11. Epilepsy. The Epilepsy Surgery Inventory 55 (ESI-55) was developed at the University of California[47] and covers eleven health concepts.[48] It has been used in clinical studies to investigate life pre and post surgery,[49] psychiatric disorders[50] and the subjective handicap of epilepsy.[51]
    12. Eye disease. The National Eye Institute Visual Function (VFQ-25) is a 25-item questionnaire designed to assess eye health, intended for use in clinical studies.[52] The survey has been utilized in clinical studies investigating macular degeneration,[53] congenital cataracts[54] and uveitis.[55]
    13. Fatigue. The Unidimensional Fatigue Impact Scale (U-FIS) was developed in 2009 by Galen Research primarily for the measurement of multiple sclerosis related fatigue.[56] It has been recommended for use in determining fatigue by an independent clinical research study[57] and translated into eight languages.[58]
    14. General Health.
    15. The Assessment of Quality of Life scales (AQoL) were psychometrically developed and refined over the past 30 years and are reliable and well-validated.&91;59&93; There are 4 instruments available; the AQoL-8D is the most comprehensive as it assesses HR-QoL across 8 domains - independent living, happiness, mental health, coping, relationships, self worth, pain, senses &91;60&93; (https://www.aqol.com.au).
    16. The Quality of Well-Being Scale (QWB) was developed in the 1970s, and a self-administered version called the QWB-SA was published in 1996.&91;61&93; The QWB has been used in studies investigating HIV patients&91;62&93;&91;63&93; and musculoskeletal disease,&91;64&93; amongst others.
    17. The EQ-5D is a generalised health-related quality of life measure which was developed in 1991 by the EuroQol Group.&91;65&93; It has five standard dimensions and has been translated into over 60 languages.&91;66&93; The EuroQoL has been extensively used in clinical trials, investigating a range of topics including overactive bladder,&91;67&93; attention deficit hyperactivity disorder&91;68&93; and denosumab for osteoporosis.&91;69&93;
    18. The Nottingham Health Profile (NHP) is a general patient-reported outcome designed to measure a patient’s view of their own health status, in a number of areas.&91;70&93; It can be completed in 5 minutes.&91;71&93; It was developed in 1975 and current copyright belongs to Galen Research.&91;72&93; Clinical research studies where the NHP has been utilized include investigations into erythropoiesis-stimulating agents,&91;73&93; glucocorticoid replacement therapy&91;74&93; and transcutaneous electrical nerve stimulation for tinnitus.&91;75&93;
    19. The Short Form 36 (SF-36) Health Survey is a survey of general health developed by the RAND corporation.&91;76&93; It was designed for use in clinical practice, research, health policy evaluations and population surveys.&91;77&93; It has been used in numerous studies including ones investigating giardia intestinalis,&91;78&93; breast cancer survivors&91;79&93; and Parkinson's disease.&91;80&93;
    20. The Sickness Impact Profile (SIP) was developed in 1997 by the Johns Hopkins University.&91;81&93; It consists of 136 items and has been adapted for strokes,&91;82&93; patients with ileal urinary diversions&91;83&93; and ex-ICU patients.&91;84&93;
    21. The Health Utilities Index measures health status, health-related quality of life and produces utility scores.&91;85&93; It was developed by Health Utilities Inc. in Canada.&91;86&93; It has been used in clinical studies investigating knee osteoarthritis,&91;87&93; urinary incontinence&91;88&93; and children who have been admitted to intensive care.&91;89&93;
    22. Genital herpes.
    23. The Herpes Outbreak Impact Questionnaire (HOIQ) is designed to determine the impact of recurrent genital herpes outbreaks on a patient’s life.&91;90&93; Its efficacy has been tested in an Australian clinical trial.&91;91&93;
    24. The Herpes Symptom Checklist (HSC) was developed alongside the HOIQ in order to assess daily symptoms of genital herpes outbreaks.&91;92&93; It was also used in an Australian clinical trial which tested the effectiveness of famciclovir.&91;93&93;
    25. The Recurrent genital herpes quality of life measure (RGHQoL) was developed in 1998 by Galen Research in order to assess the impact recurrent genital herpes has on quality of life.&91;94&93; It has been used in clinical trials investigating famciclovir,&91;95&93; suppressive antiviral therapy&91;96&93; and patient perspectives and quality of life.&91;97&93;&91;98&93;
    26. Growth hormone deficiency. The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure (QoL-AGHDA) was developed by Galen Research and measures the effect growth hormone deficiency has on adult patients.[99] The QoL-AGHDA has been used in numerous clinical practice and research studies worldwide[99][100][101][102][103] and is also utilized by the Pfizer International Metabolic Database (KIMS)[104] and the National Institute for Health and Care Excellence (NICE) in the UK.
    27. Kidney disease. The Kidney Disease Quality of Life (KD-QOL) Instrument was developed in 1994 by the RAND corporation.[105] It has been utilized in studies investigating thirst and xerostomia in maintenance hemodialysis patients,[106] different types of dialysis[107] and quality of life in hemodialysis patients.[108]
    28. Migraine. The Migraine Specific Quality of Life (MSQoL) was funded by the Wellcome Foundation and developed by Galen Research, as part of an international research study which was conducted in eight countries, with initial work conducted in the UK and US.[109] It has been used to assess the effect of nadolol and topiramate,[110] regular water intake[111] and using migraine patients as trainers in preventive attack management.[112]
    29. Multiple sclerosis. The Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS) was developed in 2009 by Galen Research and funded by Novartis Pharmaceuticals.[113] The PRIMUS has been used to assess the efficacy of fingolimod[114][115][116] and rivastigmine.[117] and has been translated into ten different languages.
    30. Osteoarthritis. The Osteoarthritis Quality of Life (OAQOL) questionnaire was published in 2008 and was developed at the University of Leeds, the University of Lancashire and Galen Research.[118] It has been used in clinical studies investigating prednisolone,[119] methotrexate[120] and hydroxychloroquine.[121]
    31. Pachyonychia Congenita. The Pachyonychia Congenita Quality of Life (PCQoL) was developed in 2012 to determine the effect Pachyonychia Congenita has on a patient's quality of life.[122]
    32. Rheumatoid arthritis.The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire determines the effect rheumatoid arthritis has on a patient’s quality of life.[123] The RAQoL has 30 items with a yes and no response format[124] and takes about six minutes to complete.[123] The RAQoL has been used in clinical studies in order to confirm the efficacy of tocilizumab[125][126] and infliximab.[127][128]
    33. Pulmonary hypertension.The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a disease-specific measure which assesses quality of life of patients with pulmonary hypertension.[129] It was developed in 2006[130] and has since been translated into fourteen different languages.[131] The CAMPHOR has been utilized in clinical trials which investigate the effects of treprostinil,[132][133] as well as trials which investigate sildenafil.[134][135]
    34. Psoriasis. The Psoriasis Index of Quality of Life (PSORIQOL) was the first psoriasis specific quality of life questionnaire.[136] It was developed in 2003 by Galen Research[137] and has been translated into 10 languages.[138] The PSORIQOL has been recognized by the National Institute for Health and Care Excellence (NICE) as a suitable tool for assessing disease impact[139] and has also been used in clinical studies.[140]
    35. Psoriatic arthritis. The Psoriatic Arthritis Quality of Life (PsAQoL) measures the effect that psoriatic arthritis has on a patient’s quality of life.[141] It is a self-administered, 20-item questionnaire that takes about three minutes to complete.[142] It has been translated into 30 languages and used to evaluate infliximab[143] and adalimumab.[144]
    36. Scars. The Patient-Reported Impact of Scars Measure (PRISM) was developed in 2010 by Galen Research and was the first scar specific patient-reported outcome measure.[145] It consists of two scales: one with 24 items for quality of life, and one with 13 items for symptoms.[146]
    37. Systemic lupus erythematosus.The Systemic Lupus Erythematosus Quality of Life measure (L-QoL or SLEQoL) was published in 2009 by Galen Research and was funded by the Arthritis Research Campaign.[147] It has been evaluated in two medical research studies.[148][149]

References

1. ^{{cite web|title=ACQLI|url=http://www.galen-research.com/content/measures/ACQLI%20UK%2030%20Male%20Patient%20-%20First%20page%20sample.pdf|website=Galen-Research.com|publisher=Galen Research|accessdate=11 November 2013}}
2. ^{{ClinicalTrialsGov|NCT00428090|Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease}}
3. ^{{ClinicalTrialsGov|NCT00348309|Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)}}
4. ^{{ClinicalTrialsGov|NCT00348140|Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)}}
5. ^{{cite journal |doi=10.2165/11599140-000000000-00000 |pmid=22350526 |title=Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden? |year=2012 |last1=Levy |first1=Karen |last2=Lanctôt |first2=Krista L. |last3=Farber |first3=Shale B. |last4=Li |first4=Abby |last5=Herrmann |first5=Nathan |journal=Drugs & Aging |volume=29 |issue=3 |pages=167–179}}
6. ^{{cite journal|last=Spertus|first=J.A.|author2=Winder, J.A. |author3=Dewhurst, T.A. |author4=Deyo, R.A. |author5=Prodzinski, J. |author6=McDonell, M. |author7= Fihn, S.D. |title=Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease|journal=Journal of the American College of Cardiology|year=1995|volume=25|issue=2|pages=333–341|doi=10.1016/0735-1097(94)00397-9|pmid=7829785|url=http://www.sciencedirect.com/science/article/pii/0735109794003979|accessdate=27 November 2013}}
7. ^{{cite journal|last=Jitta|first=D.J.|author2=DeJongste, M.J. |author3=Kliphuis, C.M. |author4= Staal, M.J. |title=Multimorbidity, the predominant predictor of quality-of-life, following successful spinal cord stimulation for angina pectoris|journal=Neuromodulation|year=2011|volume=14|issue=1|pages=13–18|doi=10.1111/j.1525-1403.2010.00321.x|pmid=21992156}}
8. ^{{cite journal|last=Villano|first=A|author2=Di Franco, A.; Nerla, R.; Sestito, A.; Tarzia, P.; Lamendola, P.; Di Monaco, A.; Sarullo, F.M.; Lanza, G.A.; Crea, F.|title=Effects of ivabradine and ranolazine in patients with microvascular angina pectoris|journal=The American Journal of Cardiology|year=2013|volume=112|issue=1|pages=8–13|doi=10.1016/j.amjcard.2013.02.045|pmid=23558043}}
9. ^{{cite journal|last=Andrelle|first=P.|author2=Ekre, O. |author3=Grip, L. |author4=Wahrborg, P. |author5=Albertsson, P. |author6=Eliasson, T. |author7=Jeppsson, A. |author8= Mannheimer, C. |title=Fatality, morbidity and quality of life in patients with refractory angina pectoris|journal=International Journal of Cardiology|year=2011|volume=147|issue=3|pages=377–382|doi=10.1016/j.ijcard.2009.09.538|pmid=19880202}}
10. ^{{cite journal |doi=10.1136/ard.62.1.20 |title=Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis |year=2003 |last1=Doward |first1=L C |journal=Annals of the Rheumatic Diseases |volume=62 |pages=20–6 |pmid=12480664 |last2=Spoorenberg |first2=A |last3=Cook |first3=SA |last4=Whalley |first4=D |last5=Helliwell |first5=PS |last6=Kay |first6=LJ |last7=McKenna |first7=SP |last8=Tennant |first8=A |last9=Van Der Heijde |first9=D |last10=Chamberlain |first10=MA |issue=1 |pmc=1754293}}
11. ^{{cite journal |doi=10.1186/ar2790 |pmid=19686597 |pmc=2745808 |title=Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis |year=2009 |last1=Van Der Heijde |first1=Désirée M |last2=Revicki |first2=Dennis A |last3=Gooch |first3=Katherine L |last4=Wong |first4=Robert L |last5=Kupper |first5=Hartmut |last6=Harnam |first6=Neesha |last7=Thompson |first7=Chris |last8=Sieper |first8=Joachim |journal=Arthritis Research & Therapy |volume=11 |issue=4 |pages=R124}}
12. ^{{cite journal |doi=10.1002/art.22887 |pmid=17665483 |title=Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study |year=2007 |last1=Davis |first1=John C. |last2=Revicki |first2=Dennis |last3=Van Der Heijde |first3=Désirée M. F. |last4=Rentz |first4=Anne M. |last5=Wong |first5=Robert L. |last6=Kupper |first6=Hartmut |last7=Luo |first7=Michelle P. |journal=Arthritis & Rheumatism |volume=57 |issue=6 |pages=1050–1057}}
13. ^{{cite journal |doi=10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H |title=Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study |year=2001 |last1=Marzo-Ortega |first1=Helena |last2=McGonagle |first2=Dennis |last3=O'Connor |first3=Philip |last4=Emery |first4=Paul |journal=Arthritis & Rheumatism |volume=44 |issue=9 |pages=2112–2117}}
14. ^{{cite journal |doi=10.1136/ard.62.10.1020 |title=Bone mineral density improvement in spondyloarthropathy after treatment with etanercept |year=2003 |last1=Marzo-Ortega |first1=H |journal=Annals of the Rheumatic Diseases |volume=62 |issue=10 |pages=1020–1 |pmid=12972490 |last2=McGonagle |first2=D |last3=Haugeberg |first3=G |last4=Green |first4=MJ |last5=Stewart |first5=SP |last6=Emery |first6=P |pmc=1754338}}
15. ^{{cite journal|last=Juniper|first=E.F.|author2=Guyatt, G.H. |author3=Epstein, R.S. |author4=Ferrie, P.J. |author5=Jaeschke, R. |author6= Hiller, T.K. |title=Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials|journal=Thorax|year=1992|volume=47|pages=76–83|doi=10.1136/thx.47.2.76|pmid=1549827|url=http://thorax.bmj.com/content/47/2/76|accessdate=25 November 2013|issue=2|pmc=463574}}
16. ^{{cite journal|last=Kim|first=M.A.|author2=Ye, Y.M.; Park, J.W.; Lee, J.H.; Lee, S.K.; Kim, C.W.; Jung, K.S.; Kim, J.H.; Yoo, H.S.; Kim, S.H; Shin, Y.S; Nahm, D.H.; Park, H.S.|title=A Computerized Asthma-Specific Quality of Life: A Novel Tool for Reflecting Asthma Control and Predicting Exacerbation|journal=International Archives of Allergy and Immunology|year=2013|volume=163|issue=1|pages=36–42|doi=10.1159/000356336|pmid=24247849|url=http://www.karger.com/Article/FullText/356336|accessdate=25 November 2013}}
17. ^{{cite journal|last=Cano Fuentes|first=G.|author2=Dastis Bendala, C; Morales Barroso, I; Manzanares Torne, M.L.; Fernandez Gregorio, A.; Martin Romana, L.|title=A randomised clinical trial to evaluate the effectiveness of an educational intervention developed for adult asthmatics in a primary care centre|journal=Atencion Primaria|volume=46|issue=3|pages=117–39|year=2013|doi=10.1016/j.aprim.2013.04.005|pmid=24176681|last3=Morales Barroso|first3=I|last4=Manzanares Torné|first4=M. L.|last5=Fernández Gregorio|first5=A|last6=Martín Romana|first6=L}}
18. ^{{cite journal|last=Freitas|first=D.A.|author2=Holloway, E.A. |author3=Bruno, S.S. |author4=Chaves, G.S. |author5=Fregonezi, G.A. |author6= Mendonca, K.M. |title=Breathing exercises for adults with asthma|journal=The Cochrane Database of Systematic Reviews|year=2013|issue=10|doi=10.1002/14651858.CD001277.pub3 |pmid=24085551 |volume=10 |pages=CD001277}}
19. ^{{cite journal |doi=10.1016/j.rmed.2009.11.023 |title=Development and validation of the Asthma Life Impact Scale (ALIS) |year=2010 |last1=Meads |first1=David M. |last2=McKenna |first2=Stephen P. |last3=Doward |first3=Lynda C. |last4=Pokrzywinski |first4=Robin |last5=Revicki |first5=Dennis |last6=Hunter |first6=Cameron |last7=Glendenning |first7=G. Alastair |journal=Respiratory Medicine |volume=104 |issue=5 |pages=633–43 |pmid=20053543}}
20. ^{{cite web|last=Crawford|first=SR|title=Further Developments of the Asthma Life Impact Scale (ALIS)|url=http://www.galen-research.com/content/publications/Galen-ALIS-poster.pdf|website=Galen-Research.com|publisher=Galen Research|accessdate=14 October 2013}}
21. ^{{cite journal |doi=10.1016/S1098-3015(10)62872-0 |title=Psk8 Impact of Atopic Dermatitis on the Quality-Of-Life of Parents of Children with Atopic Dermatitis |year=2005 |last1=Arnold |first1=RJG |last2=Zhou |first2=Y |last3=Wong |first3=KS |last4=Sung |first4=J |journal=Value in Health |volume=8 |issue=3 |pages=332}}
22. ^{{cite journal |doi=10.1007/s11136-004-4231-z |title=International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD) |year=2005 |last1=McKenna |first1=Stephen P. |last2=Whalley |first2=Diane |last3=Dewar |first3=Abigail L. |last4=Erdman |first4=Ruud A. M. |last5=Kohlmann |first5=Thomas |last6=Niero |first6=Mauro |last7=Baró |first7=Eva |last8=Cook |first8=Sharon A. |last9=Crickx |first9=Beatrice |last10=Frech |first10=Feride |last11=Van Assche |first11=Daniel van |journal=Quality of Life Research |volume=14 |pages=231–41 |pmid=15789957 |issue=1}}
23. ^{{cite journal |doi=10.1111/j.1468-3083.2006.01383.x |title=Treatment of paediatric atopic dermatitis with pimecrolimus (ElidelR, SDZ ASM 981): Impact on quality of life and health-related quality of life |year=2006 |last1=McKenna |first1=SP |last2=Whalley |first2=D |last3=De Prost |first3=Y |last4=Staab |first4=D |last5=Huels |first5=J |last6=Paul |first6=CF |last7=Van Assche |first7=D |journal=Journal of the European Academy of Dermatology and Venereology |volume=20 |issue=3 |pages=248–54 |pmid=16503881}}
24. ^{{cite journal |doi=10.1542/peds.110.1.e2 |title=Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children |year=2002 |last1=Wahn |first1=U. |last2=Bos |first2=J. D. |last3=Goodfield |first3=M. |last4=Caputo |first4=R. |last5=Papp |first5=K. |last6=Manjra |first6=A. |last7=Dobozy |first7=A. |last8=Paul |first8=C. |last9=Molloy |first9=S. |last10=Hultsch |first10=T. |last11=Graeber |first11=M. |last12=Cherill |first12=R. |last13=De Prost |first13=Y. |journal=Pediatrics |volume=110 |pages=e2 |pmid=12093983 |author14=Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group |issue=1 Pt 1}}
25. ^{{cite journal |doi=10.1067/mai.2002.126500 |title=Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug |year=2002 |last1=Kapp |first1=Alexander |last2=Papp |first2=Kim |last3=Bingham |first3=Ann |last4=Fölster-Holst |first4=Regina |last5=Ortonne |first5=Jean-Paul |last6=Potter |first6=Paul C. |last7=Gulliver |first7=Wayne |last8=Paul |first8=Carle |last9=Molloy |first9=Stephen |last10=Barbier |first10=Nathalie |last11=Thurston |first11=Mark |last12=De Prost |first12=Yves |journal=Journal of Allergy and Clinical Immunology |volume=110 |issue=2 |pages=277–84 |pmid=12170269 |author13=Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group}}
26. ^{{cite journal |doi=10.1016/j.jval.2011.11.028 |title=Health-Related Quality of Life Measurement in Children and Adolescents in Ibero-American Countries, 2000 to 2010 |year=2012 |last1=Rajmil |first1=Luis |last2=Roizen |first2=Mariana |last3=Psy |first3=Alfonso Urzúa |last4=Hidalgo-Rasmussen |first4=Carlos |last5=Fernández |first5=Gabriela |last6=Dapueto |first6=Juan José |journal=Value in Health |volume=15 |issue=2 |pages=312–22 |pmid=22433763 |author7=Working Group on HRQOL in Children in Ibero-American Countries}}
27. ^{{cite journal |doi=10.1016/S1098-3015(10)62870-7 |title=Psk6 Interpreting Scores on the Quality of Life Index for Atopic Dermatitis (Qoliad) |year=2005 |last1=Meads |first1=DM |last2=McKenna |first2=SP |last3=Doward |first3=LC |last4=Hampson |first4=N |last5=McGeown |first5=C |journal=Value in Health |volume=8 |issue=3 |pages=331–332}}
28. ^{{cite journal |doi=10.1016/S1098-3015(10)62005-0 |title=Psn12 Quality-Of-Life in Patients Suffering from Atopic Dermatitis in Germany |year=2003 |last1=Ehlken |first1=B |last2=Kugland |first2=B |last3=Schramm |first3=B |last4=Quednau |first4=K |last5=Berger |first5=K |journal=Value in Health |volume=6 |issue=6 |pages=787–788}}
29. ^{{cite journal |doi=10.1007/s00403-010-1082-z |title=A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results |year=2010 |last1=Lambert |first1=J. |last2=Bostoen |first2=J. |last3=Geusens |first3=B. |last4=Bourgois |first4=J. |last5=Boone |first5=J. |last6=De Smedt |first6=D. |last7=Annemans |first7=L. |journal=Archives of Dermatological Research |volume=303 |pages=57–63 |pmid=20842368 |issue=1}}
30. ^{{cite journal |doi=10.1111/j.1365-2133.2012.11113.x |title=An educational programme for patients with psoriasis and atopic dermatitis: A prospective randomized controlled trial |year=2012 |last1=Bostoen |first1=J. |last2=Bracke |first2=S. |last3=De Keyser |first3=S. |last4=Lambert |first4=J. |journal=British Journal of Dermatology |volume=167 |issue=5 |pages=1025–31 |pmid=22709422}}
31. ^{{cite journal |doi=10.1002/14651858.CD010080 |chapter=Different strategies for using topical corticosteroids for established eczema |title=Cochrane Database of Systematic Reviews |year=2012 |last1=Moed |first1=Heleen |last2=Yang |first2=Quan |last3=Oranje |first3=Arnold P |last4=Panda |first4=Saumya |last5=Van Der Wouden |first5=Johannes C |editor1-last=Moed |editor1-first=Heleen |journal=Protocols}}
32. ^{{cite journal |doi=10.1016/S1098-3015(10)63408-0 |title=Psk6 Belgian Drug Utilisation Study of Elidel® in Routine Practice in Atopic Dermatitis |year=2006 |last1=Lecomte |first1=P |last2=Lambert |first2=J |last3=Degreef |first3=H |last4=Lesaffre |first4=E |last5=De Backer |first5=M |journal=Value in Health |volume=9 |issue=6 |pages=A268}}
33. ^{{cite journal |pmid=9460955 |year=1998 |last1=Dawson |first1=J |last2=Fitzpatrick |first2=R |last3=Murray |first3=D |last4=Carr |first4=A |title=Questionnaire on the perceptions of patients about total knee replacement |volume=80 |issue=1 |pages=63–9 |journal=The Journal of Bone and Joint Surgery. British Volume |doi=10.1302/0301-620X.80B1.7859}}
34. ^{{cite journal |doi=10.1111/j.1756-185X.2010.01580.x |title=Extension from inpatients to outpatients: Validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis |year=2011 |last1=Xie |first1=Feng |last2=Ye |first2=Hua |last3=Zhang |first3=Yu |last4=Liu |first4=Xia |last5=Lei |first5=Ting |last6=Li |first6=Shu-Chuen |journal=International Journal of Rheumatic Diseases |volume=14 |issue=2 |pages=206–10 |pmid=21518321}}
35. ^{{cite journal |pmid=8171351 |year=1994 |last1=McKenna |first1=SP |last2=Hunt |first2=SM |title=A measure of family disruption for use in chickenpox and other childhood illnesses |volume=38 |issue=5 |pages=725–31 |journal=Social Science & Medicine |doi=10.1016/0277-9536(94)90463-4}}
36. ^{{cite journal |doi=10.1186/1471-2431-9-11 |title=The impact of rotavirus gastroenteritis on the family |year=2009 |last1=Mast |first1=T Christopher |last2=Demuro-Mercon |first2=Carla |last3=Kelly |first3=Claudia M |last4=Floyd |first4=Leigh |last5=Walter |first5=Emmanuel B |journal=BMC Pediatrics |volume=9 |pages=11 |pmid=19200366 |pmc=2649068}} {{open access}}
37. ^{{cite journal |doi=10.1016/j.ijnurstu.2012.07.017 |title=Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review |year=2013 |last1=Weldam |first1=Saskia W.M. |last2=Schuurmans |first2=Marieke J. |last3=Liu |first3=Rani |last4=Lammers |first4=Jan-Willem J. |journal=International Journal of Nursing Studies |volume=50 |issue=5 |pages=688–707 |pmid=22921317}}
38. ^{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|website=Galen-Research.com|publisher=Galen Research|accessdate=11 October 2013}}
39. ^{{cite journal |doi=10.1016/S0300-2896(09)72948-5 |title=Importancia de la fatiga, calidad del sueño y estado de ánimo en los pacientes con EPOC y la necesidad de disponer de instrumentos para su medición |trans-title=Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments |language=Spanish|year=2009 |last1=López-Campos |first1=José Luis |journal=Archivos de Bronconeumología |volume=45 |pages=2–6 |pmid=20116755}}
40. ^{{cite journal |doi=10.1097/00005650-200210000-00009 |title=Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel |year=2002 |last1=Amir |first1=Marianne |last2=Lewin-Epstein |first2=Noah |last3=Becker |first3=Gideon |last4=Buskila |first4=Dan |journal=Medical Care |volume=40 |issue=10 |pages=918–28 |pmid=12395025}}
41. ^{{cite journal |doi=10.1016/0168-8510(92)90005-V |title=A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS |year=1992 |last1=McKenna |first1=Stephen P. |last2=Hunt |first2=Sonja M. |journal=Health Policy |volume=22 |issue=3 |pages=321–30 |pmid=10122731}}
42. ^{{cite journal |pmid=14639509 |year=2003 |last1=Baca Baldomero |first1=E |last2=Cervera Enguix |first2=S |last3=Grupo De Estudio |first3=Teseo |title=Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release |volume=31 |issue=6 |pages=331–8 |journal=Actas Espanolas de Psiquiatria}}
43. ^{{cite journal |doi=10.1016/S0022-3956(02)00060-2 |title=Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression |year=2002 |last1=Detke |first1=Michael J. |last2=Lu |first2=Yili |last3=Goldstein |first3=David J. |last4=McNamara |first4=Robert K. |last5=Demitrack |first5=Mark A. |journal=Journal of Psychiatric Research |volume=36 |issue=6 |pages=383–90 |pmid=12393307}}
44. ^{{cite journal |doi=10.1186/1471-244X-7-43 |title=Duloxetine in the treatment of major depressive disorder: An open-label study |year=2007 |last1=Hudson |first1=James I |last2=Perahia |first2=David G |last3=Gilaberte |first3=Inmaculada |last4=Wang |first4=Fujun |last5=Watkin |first5=John G |last6=Detke |first6=Michael J |journal=BMC Psychiatry |volume=7 |pages=43 |pmid=17725843 |pmc=2018694}} {{open access}}
45. ^{{cite journal |pmid=16841626 |year=2006 |last1=Kornstein |first1=SG |last2=Wohlreich |first2=MM |last3=Mallinckrodt |first3=CH |last4=Watkin |first4=JG |last5=Stewart |first5=DE |title=Duloxetine efficacy for major depressive disorder in male vs. Female patients: Data from 7 randomized, double-blind, placebo-controlled trials |volume=67 |issue=5 |pages=761–70 |journal=The Journal of Clinical Psychiatry |doi=10.4088/JCP.v67n0510}}
46. ^{{cite journal |pmid=15014623 |year=2001 |last1=Dunner |first1=DL |last2=Kwong |first2=WJ |last3=Houser |first3=TL |last4=Richard |first4=NE |last5=Donahue |first5=RM |last6=Khan |first6=ZM |title=Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment with Bupropion Sustained Release: A Study in Patients with Major Depression |volume=3 |issue=1 |pages=10–16 |pmc=181153 |journal=Primary Care Companion to the Journal of Clinical Psychiatry |doi=10.4088/PCC.v03n0103}}
47. ^{{cite journal|last=Vickrey|first=B.G.|title=A procedure for developing a quality-of-life measure for epilepsy surgery patients|journal=Epilepsia|year=1993|volume=34|issue=Suppl. 4|pages=S22–S27|pmid=8348900|doi=10.1111/j.1528-1157.1993.tb05912.x}}
48. ^{{cite web|title=Epilepsy Surgery Inventory 55 Survey (ESI-55)|url=http://www.rand.org/health/surveys_tools/esi.html|website=RAND.org|publisher=RAND Health|accessdate=27 November 2013}}
49. ^{{cite journal|last=Selai|first=C.E.|author2=Elstner, K |author3=Trimble, M.R. |title=Quality of life pre and post epilepsy surgery|journal=Epilepsy Research|year=2000|volume=38|issue=1|pages=67–74|url=http://www.epires-journal.com/article/S0920-1211(99)00075-3/abstract|accessdate=27 November 2013|pmid=10604607|doi=10.1016/s0920-1211(99)00075-3}}
50. ^{{cite journal|last=de Conceicao|first=P.O.|author2=Nascimento, P.P. |author3=Mazetto, L. |author4=Alonso, N.B. |author5=Yacubian, E.M. |author6= de Araujo Filho, G.M. |title=Are psychiatric disorders exclusion criteria for video-EEG monitoring and epilepsy surgery in patients with mesial temporal sclerosis?|journal=Epilepsy & Behavior|year=2013|volume=27|issue=2|pages=310–314|doi=10.1016/j.yebeh.2013.02.014|pmid=23523814|url=http://www.sciencedirect.com/science/article/pii/S1525505013000644|accessdate=27 November 2013}}
51. ^{{cite journal|last=Monteiro Ede|first=A.|author2=Osorio Fde, L.; Veriano, A Jr.; Molina, R.S.; Funayama, S.S.; Terra, V.C.; Velasco, T.R.;Guarnieri, R.; Bianchin, M.; Assirati, J.A. Jr.; Sakamoto, A.C.; Hallak, J.E.|title=Validation of the Subjective Handicap of Epilepsy (SHE) in Brazilian patients with epilepsy|journal=Epilepsy & Behavior|year=2012|volume=24|issue=3|pages=345–351|doi=10.1016/j.yebeh.2012.04.129|pmid=22658433|url=http://www.sciencedirect.com/science/article/pii/S152550501200337X|accessdate=27 November 2013}}
52. ^{{cite journal|last=Mangione|first=Carol M.|author2=Lee, Paul P. |author3=Gutierrez, Peter R. |author4=Spritzer, Karen |author5=Berry, Sandra |author6= Hays, Ron D. |title=Development of the 25-list-item National Eye Institute Visual Function Questionnaire|journal=Archives of Ophthalmology|year=2001|volume=119|issue=7|pages=1050–1058|doi=10.1001/archopht.119.7.1050|pmid=11448327|url=http://archopht.jamanetwork.com/article.aspx?articleid=267134|accessdate=26 November 2013}}
53. ^{{cite journal|last=Orr|first=Peggy|author2=Rentz, Anne M. |author3=Margolis, Mary Kay |author4=Revicki, Dennis A. |author5=Dolan, Chantal M. |author6=Colman, Shoshana |author7=Fine, Jennifer T. |author8= Bressler, Neil M. |title=Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration|journal=Investigative Ophthalmology and Visual Science|year=2011|volume=52|issue=6|pages=3354–3359|doi=10.1167/iovs.10-5645|pmid=21282568|url=http://www.iovs.org/content/52/6/3354.long|accessdate=26 November 2013}}
54. ^{{cite journal|last=Kirwan|first=Caitriona|author2=Lanigan, Bernadette; O'Keefe, Michael|title=Vision-Related Quality of Life Assessment Using the NEI-VFQ-25 in Adolescents and Young Adults With a History of Congenital Cataract|journal=Journal of Pediatric Ophthalmology and Strabismus|year=2012|volume=49|issue=1|pages=26–31|doi=10.3928/01913913-20110517-02|pmid=21598855|url=http://www.healio.com/ophthalmology/journals/jpos/%7B749e39aa-ab97-4b64-bff0-776af5b721a7%7D/vision-related-quality-of-life-assessment-using-the-nei-vfq-25-in-adolescents-and-young-adults-with-a-history-of-congenital-cataract#|accessdate=26 November 2013}}
55. ^{{cite journal|last=Naik|first=Rupali K.|author2=Gries, Katharine S. |author3=Rentz, Anne M. |author4=Kowalski, Jonathan W. |author5= Revicki, Dennis A. |title=Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis|journal=Quality of Life Research|volume=22|issue=10|pages=2801–8|year=2013|doi=10.1007/s11136-013-0412-y|pmid=23645458}}
56. ^{{cite journal |doi=10.1177/1352458509106714 |title=The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS) |year=2009 |last1=Meads |first1=D. |last2=Doward |first2=L. |last3=McKenna |first3=S. |last4=Fisk |first4=J. |last5=Twiss |first5=J. |last6=Eckert |first6=B. |journal=Multiple Sclerosis |volume=15 |issue=10 |pages=1228–38 |pmid=19556314}}
57. ^{{cite journal |doi=10.1007/s11136-011-0009-2 |title=Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: A systematic review of measurement properties |year=2011 |last1=Elbers |first1=Roy G. |last2=Rietberg |first2=Marc B. |last3=Van Wegen |first3=Erwin E. H. |last4=Verhoef |first4=John |last5=Kramer |first5=Sharon F. |last6=Terwee |first6=Caroline B. |last7=Kwakkel |first7=Gert |journal=Quality of Life Research |volume=21 |issue=6 |pages=925–44 |pmid=22012025 |pmc=3389599}}
58. ^{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|website=Galen-Research.com|publisher=Galen Research|accessdate=20 November 2013}}
59. ^{{cite journal |vauthors=Richardson J, Iezzi A, Khan M, Maxwell A |title=Validity and Reliability of the Assessment of Quality of Life (AQoL)-8D Multi-Attribute Utility Instrument |journal=The Patient-Patient Centered Outcomes |volume=7 |issue=1 |pages=85–96 |year=2014 |doi=10.1007/s40271-013-0036-x |pmid=24271592 |pmc=3929769 }}
60. ^{{cite journal |vauthors=Maxwell A, ((Özmen M)), Iezzi A, Richardson J |title=Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data |journal=Quality of Life Research |volume=25 |issue=7 |pages=3209–3219 |year=2016 |doi=10.1007/s11136-016-1337-z |pmid=27344318 }}
61. ^{{cite book|last=Kattan|first=Michael|title=Encyclopedia of Medical Decision Making|year=2009|publisher=SAGE Publications |isbn=978-1-4129-7198-0|url=http://knowledge.sagepub.com/view/medical/n273.xml}}
62. ^{{cite journal |doi=10.1023/A:1018456031659 |year=1997 |last1=Kaplan |first1=R. M. |last2=Patterson |first2=T. L. |last3=Kerner |first3=D. N. |last4=Atkinson |first4=J. |last5=Heaton |first5=R. K. |last6=Grant |first6=I. |journal=Quality of Life Research |volume=6 |issue=6 |pages=507–14 |pmid=9330551 |title=The Quality of Well-Being scale in asymptomatic HIV-infected patients. HNRC Group. HIV Neural Behavioral Research Center}}
63. ^{{cite journal |doi=10.1177/0272989X9701700409 |title=Construct Validities of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey for HIV-infected Patients |year=1997 |last1=Hughes |first1=T. E. |last2=Kaplan |first2=R. M. |last3=Coons |first3=S. J. |last4=Draugalis |first4=J. R. |last5=Johnson |first5=J. A. |last6=Patterson |first6=T. L. |journal=Medical Decision Making |volume=17 |issue=4 |pages=439–46 |pmid=9343802|citeseerx=10.1.1.1004.6037 }}
64. ^{{cite journal |doi=10.1002/art.20071 |pmid=14872452 |title=Validity of self-administered quality of well-being scale in musculoskeletal disease |year=2004 |last1=Frosch |first1=Dominick L. |last2=Kaplan |first2=Robert M. |last3=Ganiats |first3=Theodore G. |last4=Groessl |first4=Erik J. |last5=Sieber |first5=William J. |last6=Weisman |first6=Michael H. |journal=Arthritis & Rheumatism |volume=51 |issue=1 |pages=28–33}}
65. ^{{cite journal |doi=10.1016/0168-8510(96)00822-6 |title=EuroQol: The current state of play |year=1996 |last1=Brooks |first1=Richard |journal=Health Policy |volume=37 |pages=53–72 |pmid=10158943 |issue=1}}
66. ^{{cite web|title=Euroqol EQ-5D (EQ-5D)|url=http://www.proqolid.org/instruments/euroqol_eq_5d_eq_5d?fromSearch=yes&text=yes|website=PROQOLID.org|publisher=Mapi Research Trust|accessdate=20 November 2013}}
67. ^{{cite journal |pmid=24246044 |year=2013 |last1=Desroziers |first1=K |last2=Aballéa |first2=S |last3=Maman |first3=K |last4=Nazir |first4=J |last5=Odeyemi |first5=I |last6=Hakimi |first6=Z |title=Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder |volume=11 |issue=1 |pages=200 |doi=10.1186/1477-7525-11-200 |journal=Health and Quality of Life Outcomes |pmc=3842710}} {{open access}}
68. ^{{cite journal |doi=10.1007/s10198-013-0540-x |pmid=24233919 |title=Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD |year=2013 |last1=Bouwmans |first1=Clazien |last2=Kolk |first2=Annemarie |last3=Oppe |first3=Mark |last4=Schawo |first4=Saskia |last5=Stolk |first5=Elly |last6=Agthoven |first6=Michel |last7=Buitelaar |first7=Jan |last8=Roijen |first8=Leonahakkaart |journal=The European Journal of Health Economics|volume=15 |issue=9 |pages=967–77 }}
69. ^{{cite journal |doi=10.1016/j.bone.2013.11.002 |pmid=24231131 |title=Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective |year=2013 |last1=Parthan |first1=A. |last2=Kruse |first2=M. |last3=Agodoa |first3=I. |last4=Silverman |first4=S. |last5=Orwoll |first5=E. |journal=Bone|volume=59 |pages=105–13 }}
70. ^{{cite journal |doi=10.1016/0271-7123(81)90005-5 |title=The Nottingham health profile: Subjective health status and medical consultations |year=1981 |last1=Hunt |first1=Sonja M. |last2=McKenna |first2=S.P. |last3=McEwen |first3=J. |last4=Williams |first4=Jan |last5=Papp |first5=Evelyn |journal=Social Science & Medicine. Part A: Medical Psychology & Medical Sociology |volume=15 |issue=3 |pages=221–9 |pmid=6973203}}
71. ^{{cite journal |doi=10.1136/jech.40.2.166 |title=Use of the Nottingham Health Profile with patients after a stroke |year=1986 |last1=Ebrahim |first1=S |last2=Barer |first2=D |last3=Nouri |first3=F |journal=Journal of Epidemiology & Community Health |volume=40 |issue=2 |pages=166–9 |pmid=3746178 |pmc=1052513}}
72. ^{{cite journal |pmid=3989783 |year=1985 |last1=Hunt |first1=SM |last2=McEwen |first2=J |last3=McKenna |first3=SP |title=Measuring health status: A new tool for clinicians and epidemiologists |volume=35 |issue=273 |pages=185–8 |pmc=1960139 |journal=The Journal of the Royal College of General Practitioners}}
73. ^{{cite journal |doi=10.1093/ndt/gfr697 |title=Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients |year=2011 |last1=Johansen |first1=K. L. |last2=Finkelstein |first2=F. O. |last3=Revicki |first3=D. A. |last4=Evans |first4=C. |last5=Wan |first5=S. |last6=Gitlin |first6=M. |last7=Agodoa |first7=I. L. |journal=Nephrology Dialysis Transplantation |volume=27 |issue=6 |pages=2418–25 |pmid=22187314}}
74. ^{{cite journal |doi=10.1111/j.1365-2265.2011.04074.x |title=Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients |year=2011 |last1=Behan |first1=Lucy-Ann |last2=Rogers |first2=Bairbre |last3=Hannon |first3=Mark J. |last4=O'Kelly |first4=Patrick |last5=Tormey |first5=William |last6=Smith |first6=Diarmuid |last7=Thompson |first7=Christopher J. |last8=Agha |first8=Amar |journal=Clinical Endocrinology |volume=75 |issue=4 |pages=505–13 |pmid=21521342}}
75. ^{{cite journal |doi=10.1017/S0022215106000910 |title=Treatment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life |year=2006 |last1=Aydemir |first1=G |last2=Tezer |first2=M S |last3=Borman |first3=P |last4=Bodur |first4=H |last5=Unal |first5=A |journal=The Journal of Laryngology & Otology |volume=120 |issue=6 |pmid=16556347 |pages=442–5}}
76. ^{{cite web|title=36-Item Short Form Survey from the RAND Medical Outcomes Study|url=http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html|website=RAND.org|publisher=RAND|accessdate=20 November 2013}}
77. ^{{cite journal |doi= 10.1097/00005650-199206000-00002 |title= The MOS 36-ltem Short-Form Health Survey (SF-36) |year= 1992 |last1= Ware |first1= John E. |last2= Sherbourne |first2= Cathy Donald |journal= Medical Care |volume= 30 |issue= 6 |pages= 473–83 |pmid= 1593914}}
78. ^{{cite journal |doi=10.1016/j.ajg.2013.08.004 |title=Giardia intestinalis in patients with nonulcer dyspepsia |year=2013 |last1=Abulhasan |first1=Mohamad |last2=Elshazly |first2=Tarek A. |last3=Eida |first3=Mohamad |last4=Albadry |first4=Ayman |journal=Arab Journal of Gastroenterology |volume=14 |issue=3 |pages=126–9 |pmid=24206742}}
79. ^{{cite journal |pmid=24249424 |pmc=3943705 |year=2013 |last1=Cuevas |first1=BT |last2=Hughes |first2=DC |last3=Parma |first3=DL |last4=Treviño-Whitaker |first4=RA |last5=Ghosh |first5=S |last6=Li |first6=R |last7=Ramirez |first7=AG |title=Motivation, exercise, and stress in breast cancer survivors |doi=10.1007/s00520-013-2038-6 |journal=Supportive Care in Cancer|volume=22 |issue=4 |pages=911–7 }}
80. ^{{cite journal |doi=10.1176/appi.neuropsych.12070175 |pmid=24247858 |pmc=3960993 |title=Associations of Sleep Disturbance Symptoms with Health-Related Quality of Life in Parkinson's Disease |year=2013 |last1=Avidan |first1=Alon |last2=Hays |first2=Ron D. |last3=Diaz |first3=Natalie |last4=Bordelon |first4=Yvette |last5=Thompson |first5=Alexander W. |last6=Vassar |first6=Stefanie D. |last7=Vickrey |first7=Barbara G. |journal=Journal of Neuropsychiatry |volume=25 |issue=4 |pages=319–326}}
81. ^{{cite journal |pmid=1200192 |year=1975 |last1=Gilson |first1=BS |last2=Gilson |first2=JS |last3=Bergner |first3=M |last4=Bobbit |first4=RA |last5=Kressel |first5=S |last6=Pollard |first6=WE |last7=Vesselago |first7=M |title=The sickness impact profile. Development of an outcome measure of health care |volume=65 |issue=12 |pages=1304–10 |pmc=1776251 |journal=American Journal of Public Health |doi=10.2105/AJPH.65.12.1304}}
82. ^{{cite journal |doi=10.1161/01.STR.28.11.2155 |title=A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30) |year=1997 |last1=Van Straten |first1=A. |last2=De Haan |first2=R. J. |last3=Limburg |first3=M. |last4=Schuling |first4=J. |last5=Bossuyt |first5=P. M. |last6=Van Den Bos |first6=G. A. M. |journal=Stroke |volume=28 |issue=11 |pages=2155–61 |pmid=9368557}}
83. ^{{cite journal |doi=10.5455/aim.2013.21.160-165 |title=Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions |year=2013 |last1=Prcic |first1=Alden |last2=Aganovic |first2=Damir |last3=Hadziosmanovic |first3=Osman |journal=Acta Informatica Medica |volume=21 |issue=3 |pages=160–5 |pmid=24167383 |pmc=3804474}}
84. ^{{cite journal |doi=10.1007/BF01713939 |title=Measuring quality of life with the sickness impact profile: A pilot study |year=1991 |last1=Hulsebos |first1=R. G. |last2=Beltman |first2=F. W. |last3=Dos Reis Miranda |first3=D. |last4=Spangenberg |first4=J. F. A. |journal=Intensive Care Medicine |volume=17 |issue=5 |pages=285–8 |pmid=1939874}}
85. ^{{cite journal |doi=10.1186/1477-7525-1-54 |year=2003 |last1=Horsman |first1=John |last2=Furlong |first2=William |last3=Feeny |first3=David |last4=Torrance |first4=George |journal=Health and Quality of Life Outcomes |volume=1 |pages=54 |pmid=14613568 |title=The Health Utilities Index (HUI): Concepts, measurement properties and applications |pmc=293474}} {{open access}}
86. ^{{cite journal |pmid=11491197 |year=2001 |last1=Furlong |first1=WJ |last2=Feeny |first2=DH |last3=Torrance |first3=GW |last4=Barr |first4=RD |title=The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies |volume=33 |issue=5 |pages=375–84 |journal=Annals of Medicine |doi=10.3109/07853890109002092}}
87. ^{{cite journal |doi=10.3899/jrheum.130176 |pmid=24187098 |title=Responsiveness of Health State Utility Values in Knee Osteoarthritis |year=2013 |last1=Davis |first1=E. M. |last2=Lynd |first2=L. D. |last3=Grubisic |first3=M. |last4=Kopec |first4=J. A. |last5=Sayre |first5=E. C. |last6=Cibere |first6=J. |last7=Esdaile |first7=J. |last8=Marra |first8=C. A. |journal=The Journal of Rheumatology|volume=40 |issue=12 |pages=2075–82 }}
88. ^{{cite journal |doi=10.1016/j.ajog.2013.09.025 |title=Validity of utility measures for women with urge, stress, and mixed urinary incontinence |year=2013 |last1=Harvie |first1=Heidi S. |last2=Shea |first2=Judy A. |last3=Andy |first3=Uduak U. |last4=Propert |first4=Kate |last5=Schwartz |first5=J. Sanford |last6=Arya |first6=Lily A. |journal=American Journal of Obstetrics and Gynecology|volume=210 |issue=1 |pages=85.e1–6 |pmid=24055585}}
89. ^{{cite journal |doi=10.1177/1367493513496909 |pmid=23939724 |title=Comparison of utility scores from the Visual Analog Scale and Health Utilities Index 3 in children following pediatric intensive care unit admission |year=2013 |last1=Ebrahim |first1=S. |last2=Parshuram |first2=C. |journal=Journal of Child Health Care |volume=19 |issue=1 |pages=53–62}}
90. ^{{cite journal |doi=10.1016/S1098-3015(10)61938-9 |title=Pin41 Development of the Herpes Outbreak Impact Questionnaire (Hoiq) |year=2003 |last1=Doward |first1=LC |last2=McKenna |first2=SP |last3=Meads |first3=DM |journal=Value in Health |volume=6 |issue=6 |pages=760–761}}
91. ^{{cite journal |doi=10.1111/j.1524-4733.2008.00450.x |title=Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist |year=2009 |last1=Meads |first1=David M. |last2=McKenna |first2=Stephen P. |last3=Bonney |first3=Mary-Ann |last4=Bloch |first4=Mark T. |journal=Value in Health |volume=12 |issue=2 |pages=397–400 |pmid=18783390}}
92. ^{{cite journal |doi=10.1111/j.1524-4733.2008.00424.x |title=The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire |year=2009 |last1=Doward |first1=Lynda C. |last2=McKenna |first2=Stephen P. |last3=Meads |first3=David M. |last4=Kahler |first4=Kristijan |last5=Frech |first5=Feride |journal=Value in Health |volume=12 |pages=139–45 |pmid=18647252 |issue=1}}
93. ^{{cite journal |doi=10.1016/j.jval.2011.08.193 |title=PIN5 Patient and Clinician Perceived Benefit of Early Consumption of Famciclovir for the Treatment of Herpes Outbreaks |year=2011 |last1=Twiss |first1=J. |last2=McKenna |first2=S. |last3=Bloch |first3=M. |last4=Bonney |first4=M.A. |journal=Value in Health |volume=14 |issue=7 |pages=A266}}
94. ^{{cite journal |doi=10.1023/A:1008857426633 |year=1998 |last1=Doward |first1=L. C |last2=McKenna |first2=S. P |last3=Kohlmann |first3=T |last4=Niero |first4=M |last5=Patrick |first5=D |last6=Spencer |first6=B |last7=Thorsen |first7=H. |journal=Quality of Life Research |volume=7 |issue=2 |pages=143–53 |pmid=9523496 |title=The international development of the RGHQoL: A quality of life measure for recurrent genital herpes}}
95. ^{{cite journal |doi=10.1016/j.jcv.2008.06.004 |title=Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial |year=2008 |last1=Bartlett |first1=Brenda L. |last2=Tyring |first2=Stephen K. |last3=Fife |first3=Kenneth |last4=Gnann Jr |first4=John W. |last5=Hadala |first5=Joseph T. |last6=Kianifard |first6=Farid |last7=Berber |first7=Erhan |journal=Journal of Clinical Virology |volume=43 |issue=2 |pages=190–5 |pmid=18621575}}
96. ^{{cite journal |pmid=10754944 |year=1999 |last1=Patel |first1=R |last2=Tyring |first2=S |last3=Strand |first3=A |last4=Price |first4=MJ |last5=Grant |first5=DM |title=Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection |volume=75 |issue=6 |pages=398–402 |pmc=1758256 |journal=Sexually Transmitted Infections |doi=10.1136/sti.75.6.398}}
97. ^{{cite journal |pmid=10472169 |year=1999 |last1=Spencer |first1=B |last2=Leplège |first2=A |last3=Ecosse |first3=E |title=Recurrent genital herpes and quality of life in France |volume=8 |issue=4 |pages=365–71 |journal=Quality of Life Research |doi=10.1023/A:1008904227182}}
98. ^{{cite journal |pmid=11564330 |year=2001 |last1=Patel |first1=R |last2=Boselli |first2=F |last3=Cairo |first3=I |last4=Barnett |first4=G |last5=Price |first5=M |last6=Wulf |first6=HC |title=Patients' perspectives on the burden of recurrent genital herpes |volume=12 |issue=10 |pages=640–5 |journal=International Journal of STD & AIDS |doi=10.1258/0956462011923859}}
99. ^1 {{cite journal |doi=10.1046/j.1365-2265.2000.00899.x |title=Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis |year=2000 |last1=Wirén |first1=L. |journal=Clinical Endocrinology |volume=52 |issue=2 |pages=143–52 |pmid=10671940 |last2=Whalley |first2=D |last3=McKenna |first3=S |last4=Wilhelmsen |first4=L}}
100. ^{{cite journal |doi=10.1016/j.ghir.2011.07.005 |title=Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort |year=2011 |last1=Moock |first1=Joern |last2=Friedrich |first2=Nele |last3=Völzke |first3=Henry |last4=Spielhagen |first4=Christin |last5=Nauck |first5=Matthias |last6=Koltowska-Häggström |first6=Maria |last7=Buchfelder |first7=Michael |last8=Wallaschofski |first8=Henri |last9=Kohlmann |first9=Thomas |journal=Growth Hormone & IGF Research |volume=21 |issue=5 |pages=272–8 |pmid=21865066 }}
101. ^{{cite journal |doi=10.1111/j.1524-4733.2009.00689.x |title=Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study |year=2010 |last1=Gilet |first1=Hélène |last2=Chachuat |first2=Anne |last3=Viala-Danten |first3=Muriel |last4=Auzière |first4=Sébastien |last5=Koltowska-Häggström |first5=Maria |journal=Value in Health |volume=13 |issue=4 |pages=495–500 |pmid=20102556}}
102. ^{{cite journal |doi=10.1046/j.1365-2265.1998.00634.x |title=One-year follow-up of quality of life in adults with untreated growth hormone deficiency |year=1998 |last1=Badia |first1=X. |last2=Lucas |first2=A. |last3=Sanmartí |first3=A. |last4=Roset |first4=M. |last5=Ulied |first5=A. |journal=Clinical Endocrinology |volume=49 |issue=6 |pages=765–71 |pmid=10209564}}
103. ^{{cite journal |doi=10.1210/jc.2004-0832 |title=The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy |year=2004 |last1=Mukherjee |first1=A. |last2=Tolhurst-Cleaver |first2=S. |last3=Ryder |first3=W. D. J. |last4=Smethurst |first4=L. |last5=Shalet |first5=S. M. |journal=Journal of Clinical Endocrinology & Metabolism |volume=90 |issue=3 |pages=1542–9 |pmid=15613427}}
104. ^{{cite journal |doi=10.1002/pds.1510 |title=Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database) |year=2008 |last1=Gutiérrez |first1=Lia P. |last2=Kołtowska-Häggström |first2=Maria |last3=Jönsson |first3=Peter J. |last4=Mattsson |first4=Anders F. |last5=Svensson |first5=Dag |last6=Westberg |first6=Björn |last7=Luger |first7=Anton |journal=Pharmacoepidemiology and Drug Safety |volume=17 |pages=90–102 |pmid=17957812 |issue=1}}
105. ^{{cite journal|last=Hays|first=R.D.|author2=Kallich, J.D. |author3=Mapes, D.L. |author4=Coons, S.J. |author5= Carter, W.B. |title=Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument|journal=Quality of Life Research|year=1994|volume=3|issue=5|pages=329–338|doi=10.1007/BF00451725|pmid=7841967}}
106. ^{{cite journal|last=Fan|first=W.F.|author2=Zhang, Q. |author3=Luo, L.H. |author4=Niu, J.Y. |author5= Gu, Y. |title=Study on the Clinical Significance and Related Factors of Thirst and Xerostomia in Maintenance Hemodialysis Patients|journal=Kidney and Blood Pressure Research|year=2013|volume=37|issue=4–5|pages=464–474|doi=10.1159/000355717|pmid=24247643|url=http://www.karger.com/Article/FullText/355717|accessdate=25 November 2013 }}
107. ^{{cite journal|last=Cortes-Sanabria|first=Laura|author2=Paredes-Cesena, Carlos A. |author3=Herrera-Llamas, Rebeca M. |author4=Cruz-Bueno, Yolanda |author5=Soto-Molina, Herman |author6=Pazarin, Leonardo |author7=Cortes, Margarita |author8= Martinez-Ramirez, Hector R. |title=Comparison of Cost-Utility Between Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|journal=Archives of Medical Research|year=2013|doi=10.1016/j.arcmed.2013.10.017|pmid=24211750|volume=44|issue=8|pages=655–61}}
108. ^{{cite journal|last=Fidan|first=F.|author2=Alkan, B.M. |author3=Tosun, A. |author4=Altunoglu, A |author5= Ardicoglu, O. |title=Quality of life and correlation with musculoskeletal problems, hand disability and depression in patients with hemodialysis|journal=International Journal of Rheumatic Disease|volume=19|issue=2|pages=159–166|year=2013|doi=10.1111/1756-185X.12171|pmid=24176031}}
109. ^{{cite journal |doi=10.1046/j.1526-4610.2000.00086.x |title=Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure |year=2000 |last1=Patrick |first1=Donald L. |last2=Hurst |first2=Bryan C. |last3=Hughes |first3=Janette |journal=Headache: The Journal of Head and Face Pain |volume=40 |issue=7 |pages=550–560}}
110. ^{{cite journal |doi=10.1111/j.1468-2982.2007.01367.x |title=Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients |year=2007 |last1=Garcia-Monco |first1=JC |last2=Foncea |first2=N |last3=Bilbao |first3=A |last4=Ruiz De Velasco |first4=I |last5=Gomez-Beldarrain |first5=M |journal=Cephalalgia |volume=27 |issue=8 |pages=920–8 |pmid=17645757}}
111. ^{{cite journal |doi=10.1093/fampra/cmr112 |title=A randomized trial on the effects of regular water intake in patients with recurrent headaches |year=2011 |last1=Spigt |first1=M. |last2=Weerkamp |first2=N. |last3=Troost |first3=J. |last4=Van Schayck |first4=C. P. |last5=Knottnerus |first5=J. A. |journal=Family Practice |volume=29 |issue=4 |pages=370–5 |pmid=22113647}}
112. ^{{cite journal |pmid=18197883 |year=2008 |last1=Mérelle |first1=SY |last2=Sorbi |first2=MJ |last3=Van Doornen |first3=LJ |last4=Passchier |first4=J |title=Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: Short-term effects of a randomized controlled trial |volume=28 |issue=2 |pages=127–38 |doi=10.1111/j.1468-2982.2007.01472.x |journal=Cephalalgia |doi-broken-date=2019-03-14 }}
113. ^{{cite journal |doi=10.1177/1352458509106513 |title=The development of patient-reported outcome indices for multiple sclerosis (PRIMUS) |year=2009 |last1=Doward |first1=L. |last2=McKenna |first2=S. |last3=Meads |first3=D. |last4=Twiss |first4=J |last5=Eckert |first5=B. |journal=Multiple Sclerosis |volume=15 |issue=9 |pages=1092–102 |pmid=19556315}}
114. ^{{cite journal |doi=10.1177/1352458512459019 |title=Poster I |year=2012 |journal=Multiple Sclerosis Journal |volume=18 |issue=4 Suppl |pages=55–277}}
115. ^{{cite conference |last1=van Lokven |first1=T. |last2=Kempcke |first2=R. |last3=Ziemssen |first3=T. |last4=Meergans |first4=M. |title=Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA) |booktitle=5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis |date=October 20, 2011 |location=Amsterdam, The Netherlands |url=http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137571&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900 |accessdate=October 9, 2013 }}{{dead link|date=May 2017 |bot=InternetArchiveBot |fix-attempted=yes }}
116. ^{{cite journal|last=Cascione|first=Mark|author2=Wynn, Daniel |author3=Agashivala, Neetu |author4=McCague, Kevin |author5=Pestreich, Linda |author6=Schofield, Lesley |author7=Kim, Edward |author8= Barbato, Luigi |title=Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod|journal=Neurology|date=12 February 2013|volume=80|issue=1|url=http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/P03.222|accessdate=9 October 2013}}
117. ^{{cite journal |doi=10.1177/1352458512463481 |title=Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients |year=2012 |last1=Maurer |first1=M. |last2=Ortler |first2=S. |last3=Baier |first3=M. |last4=Meergans |first4=M. |last5=Scherer |first5=P. |last6=Hofmann |first6=W. |last7=Tracik |first7=F. |journal=Multiple Sclerosis Journal |volume=19 |issue=5 |pages=631–8 |pmid=23069874}}
118. ^{{cite journal |doi=10.1002/art.23714 |pmid=18512719 |title=Development and validation of a needs-based quality of life instrument for osteoarthritis |year=2008 |last1=Keenan |first1=Anne-Maree |last2=McKenna |first2=Stephen P. |last3=Doward |first3=Lynda C. |last4=Conaghan |first4=Philip G. |last5=Emery |first5=Paul |last6=Tennant |first6=Alan |journal=Arthritis & Rheumatism |volume=59 |issue=6 |pages=841–848}}
119. ^{{cite web|title=Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011173-32/GB|website=EU Clinical Trials Register|publisher=European Medicines Agency|accessdate=20 November 2013}}
120. ^{{cite web|title=An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008237-11/GB|website=EU Clinical Trials Register|publisher=European Medicines Agency|accessdate=20 November 2013}}
121. ^{{cite web|title=HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004300-38/GB|website=Eu Clinical Trials Register|publisher=European Medicines Council|accessdate=20 November 2013}}
122. ^{{cite journal |doi=10.2310/7750.2014.14017|title=PCQoL: A Quality of Life Assessment Measure for Pachyonychia Congenita |year=2014 |last1=Abbas |first1=M. |last2=Schwartz |first2=M. |last3=Smith |first3=F.J.D. |last4=McLean |first4=W.H.I. |last5=Hull |first5=P. |journal=Journal of Cutaneous Medicine and Surgery |volume=19 |issue=1 |pages=57–65 |pmid=25775665 }}
123. ^1 {{cite journal |doi=10.1093/rheumatology/36.8.878 |title=The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument |year=1997 |last1=De Jong |first1=Z. |last2=Van Der Heijde |first2=D. |last3=McKenna |first3=S. P. |last4=Whalley |first4=D. |journal=Rheumatology |volume=36 |issue=8 |pages=878–883}}
124. ^{{cite journal |doi=10.1093/rheumatology/kes296 |title=Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology |year=2012 |last1=Adams |first1=J. |last2=Chapman |first2=J. |last3=Bradley |first3=S. |last4=Ryan |first4=S. J. |journal=Rheumatology |volume=52 |issue=3 |pages=460–4 |pmid=23118412}}
125. ^{{cite journal |doi=10.1136/annrheumdis-2011-201282 |title=Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |year=2012 |last1=Dougados |first1=M. |last2=Kissel |first2=K. |last3=Sheeran |first3=T. |last4=Tak |first4=P. P. |last5=Conaghan |first5=P. G. |last6=Mola |first6=E. M. |last7=Schett |first7=G. |last8=Amital |first8=H. |last9=Navarro-Sarabia |first9=F. |last10=Hou |first10=A. |last11=Bernasconi |first11=C. |last12=Huizinga |first12=T. |journal=Annals of the Rheumatic Diseases |volume=72 |pages=43–50 |pmid=22562983 |issue=1 |pmc=3551223}}
126. ^{{cite web|title=Efficacy of tocilizumab in patients with rheumatoid arthritis|url=http://www.controlled-trials.com/ISRCTN21216199|website=Current Controlled Trials|publisher=Springer Science+Business Media.|accessdate=2 October 2013}}
127. ^{{cite journal |doi=10.1002/art.20712 |pmid=15641102 |title=Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial |year=2005 |last1=Quinn |first1=Mark A. |last2=Conaghan |first2=Philip G. |last3=O'Connor |first3=Philip J. |last4=Karim |first4=Zunaid |last5=Greenstein |first5=Adam |last6=Brown |first6=Andrew |last7=Brown |first7=Clare |last8=Fraser |first8=Alexander |last9=Jarret |first9=Stephen |last10=Emery |first10=Paul |journal=Arthritis & Rheumatism |volume=52 |issue=1 |pages=27–35}}
128. ^{{cite journal |doi=10.1093/rheumatology/keq194 |title=Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis |year=2010 |last1=Bejarano |first1=V. |last2=Conaghan |first2=P. G. |last3=Quinn |first3=M. A. |last4=Saleem |first4=B. |last5=Emery |first5=P. |journal=Rheumatology |volume=49 |issue=10 |pages=1971–4 |pmid=20595536}}
129. ^{{cite journal |doi=10.1186/1477-7525-6-65 |title=Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses |year=2008 |last1=McKenna |first1=Stephen P |last2=Ratcliffe |first2=Julie |last3=Meads |first3=David M |last4=Brazier |first4=John E |journal=Health and Quality of Life Outcomes |volume=6 |pages=65 |pmid=18718016 |pmc=2546377}} {{open access}}
130. ^{{cite journal |doi=10.1007/s11136-005-3513-4 |title=The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension |year=2006 |last1=McKenna |first1=S. P. |last2=Doughty |first2=N. |last3=Meads |first3=D. M. |last4=Doward |first4=L. C. |last5=Pepke-Zaba |first5=J. |journal=Quality of Life Research |volume=15 |pages=103–15 |pmid=16411035 |issue=1}}
131. ^{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|website=Galen-Research.com|publisher=Galen Research|accessdate=2 October 2013}}
132. ^{{cite journal |doi=10.2147/DDDT.S19281 |title=Inhaled treprostinil: A therapeutic review |year=2012 |last1=Channick |first1=Richard |last2=Voswinckel |last3=Rubin |first3=Lewis |last4=Vultaggio |journal=Drug Design, Development and Therapy |pages=19–28 |pmid=22291467 |volume=6 |pmc=3267519}}
133. ^{{cite journal |doi=10.1186/1477-7525-11-31 |title=Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension |year=2013 |last1=Chen |first1=Hubert |last2=Rosenzweig |first2=Erika B |last3=Gotzkowsky |first3=S Karl |last4=Arneson |first4=Carl |last5=Nelsen |first5=Andrew C |last6=Bourge |first6=Robert C |journal=Health and Quality of Life Outcomes |volume=11 |pages=31 |pmid=23496856 |pmc=3610124}} {{open access}}
134. ^{{cite journal |doi=10.1016/j.ijcard.2010.02.020 |title=Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy |year=2011 |last1=Tay |first1=Edgar L.W. |last2=Papaphylactou |first2=Maria |last3=Diller |first3=Gerhard Paul |last4=Alonso-Gonzalez |first4=Rafael |last5=Inuzuka |first5=Ryo |last6=Giannakoulas |first6=Georgios |last7=Harries |first7=Carl |last8=Wort |first8=Stephen John |last9=Swan |first9=Lorna |last10=Dimopoulos |first10=Konstantinos |last11=Gatzoulis |first11=Michael A. |journal=International Journal of Cardiology |volume=149 |issue=3 |pages=372–6 |pmid=20304507}}
135. ^{{cite journal |doi=10.1378/chest.07-2681 |title=Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension |year=2008 |last1=Suntharalingam |first1=Jay |last2=Treacy |first2=C. M. |last3=Doughty |first3=N. J. |last4=Goldsmith |first4=K |last5=Soon |first5=E |last6=Toshner |first6=M. R. |last7=Sheares |first7=K. K. |last8=Hughes |first8=R |last9=Morrell |first9=N. W. |last10=Pepke-Zaba |first10=J |journal=Chest |volume=134 |issue=2 |pages=229–36 |pmid=18263674}}
136. ^{{cite journal |doi=10.1111/j.1365-4632.2005.01941.x |title=Development of the US PSORIQoL: A psoriasis-specific measure of quality of life |year=2005 |last1=McKenna |first1=Stephen P. |last2=Lebwohl |first2=Mark |last3=Kahler |first3=Kristijan N. |journal=International Journal of Dermatology |volume=44 |issue=6 |pages=462–9 |pmid=15941432}}
137. ^{{cite journal |doi=10.1046/j.1365-2133.2003.05492.x |title=Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials |year=2003 |last1=McKenna |first1=S.P. |last2=Cook |first2=S.A. |last3=Whalley |first3=D. |last4=Doward |first4=L.C. |last5=Richards |first5=H.L. |last6=Griffiths |first6=C.E.M. |last7=Van Assche |first7=D. |authorlink6=Chris Griffiths (dermatologist) |journal=British Journal of Dermatology |volume=149 |issue=2 |pages=323–31 |pmid=12932239}}
138. ^{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|website=Galen-Research.com|publisher=Galen Research|accessdate=13 November 2013}}
139. ^{{cite web|title=Psoriasis: management of psoriasis|url=http://www.nice.org.uk/nicemedia/live/12344/58871/58871.pdf|website=NICE.org.uk|publisher=National Institute for Health and Care Excellence|accessdate=13 November 2013|deadurl=yes|archiveurl=https://web.archive.org/web/20131113124018/http://www.nice.org.uk/nicemedia/live/12344/58871/58871.pdf|archivedate=13 November 2013|df=}}
140. ^{{cite web|title=CAEB071C2201|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007160-19/GB|website=ClinicalTrialsRegister.eu|publisher=EU Clinical Trials Register|accessdate=13 November 2013}}
141. ^{{cite journal |doi=10.3109/03009740903468982 |title=Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: Results from a cross-sectional survey |year=2010 |last1=Brodszky |first1=V |last2=Péntek |first2=M |last3=Bálint |first3=PV |last4=Géher |first4=P |last5=Hajdu |first5=O |last6=Hodinka |first6=L |last7=Horváth |first7=G |last8=Koó |first8=É |last9=Polgár |first9=A |last10=Seszták |first10=M |last11=Szántó |first11=S |last12=Ujfalussy |first12=I |last13=Gulácsi |first13=L |journal=Scandinavian Journal of Rheumatology |volume=39 |issue=4 |pages=303–9 |pmid=20166848}}
142. ^{{cite journal |doi=10.1136/ard.2003.006296 |title=Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis |year=2004 |last1=McKenna |first1=S P |journal=Annals of the Rheumatic Diseases |volume=63 |issue=2 |pages=162–9 |pmid=14722205 |last2=Doward |first2=LC |last3=Whalley |first3=D |last4=Tennant |first4=A |last5=Emery |first5=P |last6=Veale |first6=DJ |pmc=1754880}}
143. ^{{cite journal |doi=10.1136/ard.2006.063818 |title=Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis |year=2007 |last1=Marzo-Ortega |first1=H. |last2=McGonagle |first2=D. |last3=Rhodes |first3=L. A |last4=Tan |first4=A. |last5=Conaghan |first5=P. G |last6=O'Connor |first6=P. |last7=Tanner |first7=S. F |last8=Fraser |first8=A. |last9=Veale |first9=D. |last10=Emery |first10=P. |journal=Annals of the Rheumatic Diseases |volume=66 |issue=6 |pages=778–81 |pmid=17185324 |pmc=1954680}}
144. ^{{ClinicalTrialsGov|NCT00427362|A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)}}
145. ^{{cite journal |doi=10.1097/PRS.0b013e3181d4fd89 |title=The Patient-Reported Impact of Scars Measure: Development and Validation |year=2010 |last1=Brown |first1=Benjamin C. |last2=McKenna |first2=Stephen P. |last3=Solomon |first3=Mattea |last4=Wilburn |first4=Jeanette |last5=McGrouther |first5=Duncan A. |last6=Bayat |first6=Ardeshir |journal=Plastic and Reconstructive Surgery |volume=125 |issue=5 |pages=1439–49 |pmid=20440163}}
146. ^{{cite journal |doi=10.1016/S1098-3015(10)75273-6 |title=Pss36 Development and Validation of the Patient-Reported Impact of Scars Measure (Prism) |year=2009 |last1=Wilburn |first1=J |last2=McKenna |first2=SP |last3=Brown |first3=B |last4=Solomon |first4=M |last5=McGrouther |first5=DA |last6=Bayat |first6=A |journal=Value in Health |volume=12 |issue=7 |pages=A459}}
147. ^{{cite journal |doi=10.1136/ard.2007.086009 |title=The development of the L-QoL: A quality-of-life instrument specific to systemic lupus erythematosus |year=2009 |last1=Doward |first1=L C |last2=McKenna |first2=S P |last3=Whalley |first3=D |last4=Tennant |first4=A |last5=Griffiths |first5=B |last6=Emery |first6=P |last7=Veale |first7=D J |journal=Annals of the Rheumatic Diseases |volume=68 |issue=2 |pages=196–200 |pmid=18385276}}
148. ^{{cite journal |doi=10.1093/rheumatology/kes370 |title=Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: A review of the literature |year=2012 |last1=Castelino |first1=M. |last2=Abbott |first2=J. |last3=McElhone |first3=K. |last4=Teh |first4=L.-S. |journal=Rheumatology |volume=52 |issue=4 |pages=684–96 |pmid=23264550}}
149. ^{{cite journal |doi=10.1002/acr.20636 |pmid=22588761 |title=Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire |year=2011 |last1=Yazdany |first1=Jinoos |journal=Arthritis Care & Research |volume=63 |issue=11 |pages=S413–S419|pmc=3437754 }}
{{DEFAULTSORT:Patient-reported quality of life surveys}}

1 : Medical lists
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/23 3:27:38